US EditionNew molecular target identified for pancreatic cancer treatment
- Researchers at City of Hope identified a new molecular target for pancreatic cancer treatment.
- Pancreatic cancer often evades treatments, and few therapeutic options exist for patients.
- Scientists targeted transcription-replication conflicts using AOH1996, an experimental drug from City of Hope.
- Two patients with tumors resistant to chemotherapy showed up to 49% liver metastases shrinkage after taking AOH1996.
- Larger studies are needed, but this approach could transform the genetic culprit into a therapeutic ally.
19 Articles
19 Articles
Ablative RT Shows Promise in Technically Resectable Pancreatic Cancer
(MedPage Today) -- The use of ablative radiation therapy (A-RT) led to promising overall survival and effective local tumor control in patients with technically resectable pancreatic ductal adenocarcinoma (PDAC) who were high-risk candidates for...
New molecular target identified for pancreatic cancer treatment
Researchers at City of Hope®, one of the largest and most advanced cancer research and treatment organizations in the U.S. with its National Medical Center named top 5 in the nation for cancer by U.S. News & World Report, have identified a new molecular target for treating pancreatic cancer, reports a Gastroenterology study published today.
Targeted new approach to treat pancreatic cancer
Researchers have identified a new molecular target for treating pancreatic cancer. Scientists focused on transcription-replication conflicts (TRCs), which occur when the mechanisms responsible for gene expression and genome duplication collide. The clash disrupts cells' ability to read and copy genes, leading to replication stress, a frequent phenomenon in pancreatic cancer. The added stress causes cells to make errors copying their DNA, enablin…
Coverage Details
Bias Distribution
- 83% of the sources are Center
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
